Evidence map›Paper›PMID 41179115›Full record

ArticleTherapeutic advances in medical oncology2025

Treatment beyond progression and rechallenge with pyrotinib in HER2-positive metastatic breast cancer and brain metastases: a multicenter real-world study.

Jing Peng, Qitong Chen, Liping Liu, Ning Xie, Mingwen Liu, Xuan Liu, Liyuan Qian, Kaili Lu, Tao Wu, Haiqing Xie and 18 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in medical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Jing PengDepartment of General Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Qitong ChenDepartment of General Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Liping LiuBreast Internal Medicine Department, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Ning XieBreast Internal Medicine Department, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Mingwen LiuDepartment of Breast Surgery, The First People's Hospital of Xiangtan City, Xiangtan, Hunan, China.
Xuan LiuDepartment of Breast Surgery, The First People's Hospital of Xiangtan City, Xiangtan, Hunan, China.
Liyuan QianDepartment of Breast and Thyroid Surgery, Third Xiangya Hospital, Central South University, Changsha, China.
Kaili LuDepartment of Oncology, Yiyang Central Hospital, Yiyang, China.
Tao WuDepartment of Oncology, The First People's Hospital of Changde, Changde, China.
Haiqing XieDepartment of Breast and Thyroid Surgery, Chenzhou No. 1 People's Hospital, Chenzhou, China.
Haifan XuBreast and Thyroid Surgery, The First Affiliated Hospital of University of South China, Hengyang, China.
Zecheng HuBreast and Thyroid Surgery, The First Affiliated Hospital of University of South China, Hengyang, China.
Sijuan DingDepartment of Oncology, The Central Hospital of Yongzhou, Yongzhou, China.
Wei ZhouDepartment of Breast and Thyroid Surgery, The Affiliated ZhuZhou Hospital of Xiangya School of Medicine Central South University, Zhuzhou, China.
Chaojie ZhangDepartment of Breast and Thyroid Surgery, Hunan Provincial People's Hospital, Changsha, China.
Yan LiDepartment of Oncology, Loudi Central Hospital, Loudi, China.
Jinhui HuDepartment of Breast Surgery, The First Hospital Hunan University of Chinese Medicine, Changsha, China.
Ruilian XieDepartment of Oncology, First Affiliated Hospital of Gannan Medical University, Ganzhou, China.
Jing HeDepartment of Oncology, Ganzhou People's Hospital, Ganzhou, China.
Zhengkui SunDepartment of Breast Surgery, Jiangxi Cancer Hospital, Nanchang, China.
Feng XuDepartment of General Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Danhua ZhangDepartment of General Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Qian LongDepartment of General Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Jinfeng ZhuDepartment of General Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Xi ChenDepartment of General Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Quchang OuyangBreast Internal Medicine Department, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, No. 283, Tongzipo Road, Changsha 410013, China.
Shouman WangDepartment of Breast Surgery, Xiangya Hospital of Central South University, No. 87, Xiangya Road, Changsha, Hunan 410008, China.
Wenjun YiDepartment of General Surgery, The Second Xiangya Hospital of Central South University, and Clinical Research Center for Breast Disease in Hunan Province, No. 139, Renmin Central Road, Changsha 410011, China.ORCID https://orcid.org/0000-0002-1563-4925

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Despite significant advancements in treatment, patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) continue to face the challenge of drug resistance, highlighting the need to develop new drugs and treatment strategies. Pyrotinib has exhibited notable efficacy in managing HER2-positive MBC, especially in individuals with brain metastasis (BM). However, real-world evidence on the effectiveness of pyrotinib re-treatment remains limited. Objectives: This study aims to assess the efficacy of pyrotinib re-treatment-including treatment beyond progression (TBP) and rechallenge-in patients with HER2-positive MBC, particularly those with BMs, in a real-world clinical setting. Design: A retrospective, multicenter, real-world study. Methods: Patients with HER2-positive MBC who experienced progression during pyrotinib treatment and subsequently continued or resumed pyrotinib-based regimens were enrolled. Patients were divided into two groups according to the re-treatment pattern: the pyrotinib TBP group and the pyrotinib rechallenge group. The endpoints were progression-free survival (PFS) and overall survival (OS). Results: A total of 226 participants received pyrotinib TBP, whereas 33 received pyrotinib rechallenge. The median PFS of pyrotinib re-treatment (7.2 vs 6.3 months, Conclusion: Pyrotinib TBP and pyrotinib rechallenge both demonstrate potential benefits for patients with HER2-positive MBC, including those with BM.

Indexed as

brain metastasesHER2-positive metastatic breast cancerspyrotinibrechallengere-treatmenttreatment beyond progressiontyrosine kinase inhibitor

Identifiers

PMID41179115
PMCPMC12575939

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.